Chemotherapy News and Research

Latest Chemotherapy News and Research

Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

Cell Therapeutics, Inc. announced that data from a study with OPAXIO, in patients with newly diagnosed high-grade gliomas, and interim results from a study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia, will be presented at the 2011 American Society of Clinical Oncology Annual Meeting, which will be held June 3-7, 2011, in Chicago, Illinois. Both studies were selected for oral poster discussion sessions.

12 May 2011

Reprogrammed herpes virus can improve early cancer diagnosis

Scientists have used a genetically re-engineered herpes virus that selectively hunts down and infects cancerous tumors and then delivers genetic material that prompts cancers to secrete a biomarker and reveal their presence.

12 May 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

Women with invasive breast cancer can benefit from new genomic test

A new genomic test combining multiple signatures - a patient's estrogen receptor status, endocrine therapy response, chemotherapy resistance and sensitivity - shows promise as a predictor of chemotherapy response and survival benefit in women with invasive breast cancer, according to research led by The University of Texas MD Anderson Cancer Center.

11 May 2011

Genentech submits vemurafenib NDA for BRAF V600 mutation-positive metastatic melanoma

Genentech, a member of the Roche Group, today announced that the company submitted a New Drug Application for vemurafenib to the U.S. Food and Drug Administration for people with BRAF V600 mutation-positive metastatic melanoma, and that Roche submitted a Marketing Authorization Application to the European Medicines Agency for vemurafenib in the same indication.

11 May 2011

Sosei acquires rights to Loramyc in Japan from BioAlliance Pharma

Sosei Group Corporation, the biopharmaceutical company, today announces that Sosei Co., Ltd., its wholly owned Japanese subsidiary, acquired development and commercialization rights to Loramyc (miconazole Lauriad) in Japan from BioAlliance Pharma.

11 May 2011

Zebrafish research identifies undiscovered high-risk genetic features in T-cell acute lymphocytic leukemia

Leukemia is the most common childhood cancer; it also occurs in adults. Now researchers working with zebrafish at Huntsman Cancer Institute (HCI) at the University of Utah have identified previously undiscovered high-risk genetic features in T-cell acute lymphocytic leukemia (T-ALL), according to an article published online May 9, 2011, in the cancer research journal Oncogene.

11 May 2011

MTTI obtains exclusive license for novel fluorescence dyes from Massachusetts General Hospital

Molecular Targeting Technologies, Inc., announced that it has obtained an exclusive license from the Massachusetts General Hospital for novel fluorescence dyes developed by Scott Hilderbrand, Ph.D. Fangwei Shao, Ph.D., and Ralph Weissleder, Ph.D. M.D.

11 May 2011

Allos, Mundipharma enter strategic collaboration to co-develop FOLOTYN

Allos Therapeutics, Inc. and Mundipharma International Corporation Limited today jointly announced that the companies have entered into a strategic collaboration agreement to co-develop FOLOTYN (pralatrexate injection).

11 May 2011

UCH to hold groundbreaking ceremony for $400M expansion at Anschutz Medical Campus

The University of Colorado Hospital is holding a groundbreaking ceremony to celebrate the $400 million expansion on Tuesday, May 24, from 5 to 6:30 p.m. at the Anschutz Medical Campus.

10 May 2011

Treatment with estrogen-lowering drugs shrinks tumors and reduces mastectomy rates in breast cancer patients

In the first large trial of its kind in the United States, researchers have shown that estrogen-lowering drugs can shrink tumors and reduce mastectomy rates for patients with stage 2 or 3 breast cancer.

10 May 2011

Pfizer presents SA3Ag staphylococcal vaccine Phase 1 trial data at ECCMID/ICC

Inhibitex, Inc., announced today that Pfizer Inc. presented safety and immunogenicity data from a Phase 1 double-blind randomized placebo controlled study in 408 healthy volunteers of a novel three antigen Staphylococcus aureus investigational vaccine at the 21st European Congress of Clinical Microbiology and Infectious Diseases and 27th International Congress of Chemotherapy in Milan, Italy.

10 May 2011

EpiCept first quarter net loss decreases to $2.5 million

EpiCept Corporation today announced operating and financial results for the three months ended March 31, 2011, and provided an update with respect to the Company's key business initiatives.

10 May 2011

CHOP forms first startup firm to develop treatments for peripheral artery disease

Building on its extensive laboratory research using magnetically guided nanoparticles to deliver drugs to diseased blood vessels, The Children's Hospital of Philadelphia has just spun off its first startup company, Vascular Magnetics, Inc.

10 May 2011

OncoGenex first quarter revenue decreases to $1.2 million

OncoGenex Pharmaceuticals, Inc. today announced its first quarter financial results and provided an update on current events and activities.

10 May 2011

Boston Scientific launches Expect Endoscopic Ultrasound Aspiration Needle

Boston Scientific Corporation today announced the U.S. and international launch of its Expect™ Endoscopic Ultrasound Aspiration Needle, used for acquiring tissue samples for diagnosing and staging malignancies in organs adjacent to the gastrointestinal tract. The Expect Needle received FDA clearance and CE Mark approval earlier this year and is being marketed in the U.S., Europe and other international markets.

9 May 2011

GTx reports net loss of $2.6 million for first quarter 2011

GTx, Inc. today provided a company update and reported financial results for the first quarter of 2011.

9 May 2011

OncoSec's tumor-destroying, tissue-sparing drug/device system profiled in Medical Device Daily

OncoSec Medical Inc., a therapeutic oncology company developing innovative medical approaches to treat solid tumor cancers with unmet medical needs, announced today the cancer therapy company's tumor-destroying, tissue-sparing drug/device technology was profiled in Medical Device Daily, the news source for the high-tech medical technology industry that is relied on by thousands of industry insiders every business morning.

9 May 2011

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

Cempra Pharmaceuticals, a developer of differentiated antibiotics, today announced an oral presentation showing that intravenous (IV) solithromycin demonstrates excellent tolerability and a favorable pharmacokinetic profile at IV doses up to 800 mg.

7 May 2011

Study confirms prognostic role of CTC in metastatic breast cancer

French researchers have reported the strongest proof yet that evidence of 'circulating tumor cells' found in samples of a patient's blood is strongly linked to poor outcomes such as a short time to disease progression.

7 May 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

Reprogrammed herpes virus can improve early cancer diagnosis

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Women with invasive breast cancer can benefit from new genomic test

Genentech submits vemurafenib NDA for BRAF V600 mutation-positive metastatic melanoma

Sosei acquires rights to Loramyc in Japan from BioAlliance Pharma

Zebrafish research identifies undiscovered high-risk genetic features in T-cell acute lymphocytic leukemia

MTTI obtains exclusive license for novel fluorescence dyes from Massachusetts General Hospital

Allos, Mundipharma enter strategic collaboration to co-develop FOLOTYN

UCH to hold groundbreaking ceremony for $400M expansion at Anschutz Medical Campus

Treatment with estrogen-lowering drugs shrinks tumors and reduces mastectomy rates in breast cancer patients

Pfizer presents SA3Ag staphylococcal vaccine Phase 1 trial data at ECCMID/ICC

EpiCept first quarter net loss decreases to $2.5 million

CHOP forms first startup firm to develop treatments for peripheral artery disease

OncoGenex first quarter revenue decreases to $1.2 million

Boston Scientific launches Expect Endoscopic Ultrasound Aspiration Needle

GTx reports net loss of $2.6 million for first quarter 2011

OncoSec's tumor-destroying, tissue-sparing drug/device system profiled in Medical Device Daily

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

Study confirms prognostic role of CTC in metastatic breast cancer

Cancer Research - Second Edition eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in